Online inquiry

IVTScrip™ mRNA-Anti-CD274, MEDI4736(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ11249MR)

This product GTTS-WQ11249MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets CD274 gene. The antibody can be applied in Solid tumors, Small Cell Lung Cancer (SCLC) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_001267706.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 29126
UniProt ID Q9NZQ7
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD274, MEDI4736(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ11249MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ8800MR IVTScrip™ mRNA-Anti-PDCD1, IBI-308(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA IBI-308
GTTS-WQ13107MR IVTScrip™ mRNA-Anti-ACVRL1, PF-03446962(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA PF-03446962
GTTS-WQ12655MR IVTScrip™ mRNA-Anti-RSPO3, OMP-131R10(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA OMP-131R10
GTTS-WQ10895MR IVTScrip™ mRNA-Anti-IL1A, MABp1(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA MABp1
GTTS-WQ13674MR IVTScrip™ mRNA-Anti-TNFSF13B, RC18(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA RC18
GTTS-WQ9425MR IVTScrip™ mRNA-Anti-KLRC1, IPH-2201(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA IPH-2201
GTTS-WQ164MR IVTScrip™ mRNA-Anti-EGFR, 1-26/3-67(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA 1-26/3-67
GTTS-WQ9338MR IVTScrip™ mRNA-Anti-TNFRSF18, INCAGN-01876(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA INCAGN-01876
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW